Skip to main content

Eric Ruderman, MD

Eric Ruderman, MD

Professor of Medicine
Division of Rheumatology
Northwestern University, Feinberg School of Medicine
Chicago, Illinois

Related Videos

How do define loss of response to a DMARD-based therapy in RA? What markers do you use? Is remission always the end point?

How do define loss of response to a DMARD-based therapy in RA? What markers do you use? Is remission always the end point?

How do define loss of response to a DMARD-based therapy in RA? What markers do you use? Is remission always the end point?

How precise is our understanding of the comparative effectiveness of targeting different cytokine or immune-mediating signaling systems? How long do the effects of a biologic last?

How precise is our understanding of the comparative effectiveness of targeting different cytokine or immune-mediating signaling systems? How long do the effects of a biologic last?

How precise is our understanding of the comparative effectiveness of targeting different cytokine or immune-mediating signaling systems? How long do the effects of a biologic last?

What side effects should we be on the lookout for in patients treated with IL-6 inhibitors? And how should we manage them?

What side effects should we be on the lookout for in patients treated with IL-6 inhibitors? And how should we manage them?

What side effects should we be on the lookout for in patients treated with IL-6 inhibitors? And how should we manage them?

How do we identify RA patients that are likely to respond to inhibition of TNF vs. those likely to respond to inhibition of IL-6 cytokine?

How do we identify RA patients that are likely to respond to inhibition of TNF vs. those likely to respond to inhibition of IL-6 cytokine?

How do we identify RA patients that are likely to respond to inhibition of TNF vs. those likely to respond to inhibition of IL-6 cytokine?

What biomarkers or clinical or symptomatic metrics have you used to identify those patients who will clearly require biologic therapy as foundational approach?

What biomarkers or clinical or symptomatic metrics have you used to identify those patients who will clearly require biologic therapy as foundational approach?

What biomarkers or clinical or symptomatic metrics have you used to identify those patients who will clearly require biologic therapy as foundational approach?

What is the rationale for early DMARD therapy once the diagnosis of RA is established?

What is the rationale for early DMARD therapy once the diagnosis of RA is established?

What is the rationale for early DMARD therapy once the diagnosis of RA is established?

Upon failure of a TNFI, what is the evidence and rationale for switching to an agent with an alternative MOA, including an IL-6 inhibitor or T-cell co-modulating agent?

Upon failure of a TNFI, what is the evidence and rationale for switching to an agent with an alternative MOA, including an IL-6 inhibitor or T-cell co-modulating agent?

Upon failure of a TNFI, what is the evidence and rationale for switching to an agent with an alternative MOA, including an IL-6 inhibitor or T-cell co-modulating agent?

What are the triggers for using a biologic agent? How early in the course of the disease is initiation with a TNFI or IL-6 inhibitor warranted?

What are the triggers for using a biologic agent? How early in the course of the disease is initiation with a TNFI or IL-6 inhibitor warranted?

What are the triggers for using a biologic agent? How early in the course of the disease is initiation with a TNFI or IL-6 inhibitor warranted?

How should one optimally "sequence" therapy in patients who require biologic therapy? Is there a "one-sequence-fits-all" strategy?

How should one optimally "sequence" therapy in patients who require biologic therapy? Is there a "one-sequence-fits-all" strategy?

How should one optimally “sequence” therapy in patients who require biologic therapy? Is there a “one-sequence-fits-all” strategy?